Bactiguard (BACTI) Q3 2025 earnings summary

Executive summary

• Q3 2025 achieved positive EBITDA of SEK 5.3 million, maintaining profitability despite a 34.5% revenue decline due to lower license revenues and currency effects.

• Investments in organizational capabilities and clinical evidence support future growth in infection prevention and wound management.

• License revenue from BD rebounded, while Zimmer Biomet revenue was limited as anticipated.

• Strategic focus remains on expanding partnerships, advancing clinical validation, and infection prevention technology.

• Wound Management portfolio showed continued growth in Hydrocyn aqua, offset by a decline in sutures.

Financial highlights

• Q3 2025 revenues were SEK 48.4 million, down 34.5% year-over-year, impacted by high prior-year comparisons and currency headwinds.

• License revenues reached SEK 29.9 million, with BD partnership revenues at SEK 28.3 million, down 15% year-over-year.

• Wound management revenues were SEK 15.6 million, a 12.6% decrease from Q3 2024, mainly due to lower suture sales.

• Net loss for Q3 was SEK 7.5 million; year-to-date net loss improved to SEK 20.4 million.

• Operating expenses decreased by 22% year-to-date, with significant cost savings.

Outlook and guidance

• Wound Management is expected to deliver double-digit growth long-term, driven by Hydrocyn aqua.

• Strategic targets for 2030 include revenues of at least SEK 600 million and EBITDA of at least SEK 200 million.

• Continued investment in R&D, regulatory, and partnership expansion is planned.

• Focus remains on expanding partnerships and advancing early-stage testing in high-need therapeutic areas.

• Progress and future launches anticipated in BD partnership, with regulatory approvals pending.